Vaccine Development and the Costs of Uncertainty

Turn any article into a podcast. Upgrade now to start listening.

Vaccine Development and the Costs of Uncertainty

TL;DR

  • The FDA refused to evaluate Moderna's mRNA flu vaccine, despite a $1 billion investment and positive trial data.
  • The refusal, issued via a 'Refuse-to-File' letter, caused shock and concern within the vaccine industry regarding regulatory risks.
  • Industry experts warned that unpredictable regulations could shift investment away from vaccine development.
  • The FDA reversed its decision approximately a week later, agreeing to review the vaccine.
  • The incident is seen as an example of policy shifts under new leadership, potentially impacting trust in established regulatory processes.
  • The article links this event to the Trump administration's broader skepticism towards vaccines and mRNA technology, mentioning Health and Human Services Secretary Robert F. Kennedy Jr.

Continuer la lecture de l'article original